| Issue Date | Title | Author(s) |
| Aug-2022 | Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthere (R)) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial | Shi, Yuankai; Zhang, Qingyuan; Hong, Xiaonan; Wang, Zhen; Gao, Yuhuan; Zou, Liqun; Cen, Hong; Gui, Lin; Li, Yufu; Feng, Jifeng; Wang, Zhao; Zhang, Mingzhi; Jin, Chuan; Zhang, Weihua; Hu, Jianda; Zheng, Chengyun; Zheng, Zhendong; Zhang, Liling; Chen, Shaoshui; Huang, Yunhong; Tang, Yun; Gao, Yajie; Hao, Miaowang; Li, Xiaoling; Chang, Chunkang; Yang, Haiyan; Wu, Hui; Shen, Lida; Ke, Xiaoyan; Zhang, Liangming; Xi, Yaming; Yang, Linhua; Xie, Liangzhi; Gai, Wenlin; Ji, Yanan |
| Oct-2021 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study | Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; Xu, Jianming; Fan, Qingxia; Xu, Ruihua; Zhang, Liangming; Li, Enxiao; Sun, Yuping; Yu, Guohua; Bai, Chunmei; Liu, Yong; Zeng, Jiangzheng; Ying, Jieer; Liang, Xinjun; Xu, Nong; Gao, Chao; Shu, Yongqian; Ma, Dong; Dai, Guanghai; Li, Shengmian; Deng, Ting; Cui, Yuehong; Fang, Jianmin; Ba, Yi; Shen, Lin |
| 24-Feb-2023 | Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT) | Shi, Yuankai; Chen, Jianhua; Zhang, Helong; Zhang, Zhihong; Zhang, Yiping; Wang, Zhehai; Zhang, Shucai; Zhao, Jian; Liu, Chunling; Wang, Xiuwen; Zhao, Yanqiu; Hu, Changlu; Yang, Lei; Hao, Xuezhi; Wang, Lin; Liu, Yunpeng; Yu, Yan; Zhao, Jun; Wang, Mengzhao; Zhang, Liangming; Sun, Sanyuan; Hu, Yanping; Gu, Kangsheng; Hang, Xiaosheng; Shan, Jinlu; Zhang, Yu; Tan, Bangxian; Yang, Weihua; Yang, Runxiang; Si, Meimei; Geng, Huaize; Li, Hui; Kang, Xiaoyan |
| 20-May-2020 | A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. | Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nan-Feng; Luo, Suxia; Gong, Jifang; Li, Zhen; Gu, Kangsheng; Lu, Jin Wei; Xu, Jianming; Fan, Qingxia; Xu, Rui-hua; Zhang, Liangming; Fang, Jianmin; Ba, Yi; Shen, Lin |
| 2019 | Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study | Liang, Hongge; Song, Xia; Zhang, Yuhui; Zhang, Shucai; Li, Fang; Fang, Jian; Li, Junling; Liang, Li; Nie, Ligong; Ma, Kewei; Zhang, Liangming; Wang, Xiaohong; Xu, Junjun; Wei, Yanxia; Wang, Jinghui; Song, Qi; Tian, Guangming; Mu, Yuxin; Gu, Yangchun; Yang, Lei; Sun, Ping; Zhong, Wei; Zhao, Jing; Xu, Yan; Chen, Minjiang; Wang, Mengzhao |
